Key PointsQuestion
Is long-term intake of caffeinated and decaffeinated coffee associated with risk of dementia and cognitive outcomes?
Findings
In this prospective cohort study of 131 821 individuals from 2
cohorts with up to 43 years of follow-up, 11 033 dementia cases were
documented. Higher caffeinated coffee intake was significantly
associated with lower risk of dementia. Decaffeinated coffee intake was
not significantly associated with dementia risk.
Meaning
Higher caffeinated coffee intake was associated with more favorable cognitive outcomes.
Importance
Evidence linking coffee and tea to cognitive health remains
inconclusive, and most studies fail to differentiate caffeinated from
decaffeinated coffee.
Objective
To investigate associations of coffee and tea intake with dementia risk and cognitive function.
Design, Setting, and Participants
Prospective cohort study that included female participants
from the Nurses’ Health Study (NHS; n = 86 606 with data from 1980-2023)
and male participants from the Health Professionals Follow-up Study
(HPFS; n = 45 215 with data from 1986-2023) who did not have cancer,
Parkinson disease, or dementia at study entry (baseline) in the US.
Exposures
The primary exposures were intakes of caffeinated coffee,
decaffeinated coffee, and tea. Dietary intake was collected every 2 to 4
years using validated food frequency questionnaires.
Main Outcomes and Measures
The primary outcome was dementia, which was identified via
death records and physician diagnoses. The secondary outcomes included
subjective cognitive decline assessed by a questionnaire-based score
(range, 0-7; higher scores indicate greater perceived decline; cases
defined as those with a score ≥3) and objective cognitive function
assessed only in the NHS cohort using telephone-based neuropsychological
tests such as the Telephone Interview for Cognitive Status (TICS) score
(range, 0-41) and a measure of global cognition (a standardized mean z score for all 6 administered cognitive tests).
Results
Among 131 821 participants (mean age at baseline, 46.2 [SD,
7.2] years in the NHS cohort and 53.8 [SD, 9.7] years in the HPFS
cohort; 65.7% were female) during up to 43 years of follow-up (median,
36.8 years; IQR, 28-42 years), there were 11 033 cases of incident
dementia. After adjusting for potential confounders and pooling results
across cohorts, higher caffeinated coffee intake was significantly
associated with lower dementia risk (141 vs 330 cases per 100 000
person-years comparing the fourth [highest] quartile of consumption with
the first [lowest] quartile; hazard ratio, 0.82 [95% CI, 0.76 to 0.89])
and lower prevalence of subjective cognitive decline (7.8% vs 9.5%,
respectively; prevalence ratio, 0.85 [95% CI, 0.78 to 0.93]). In the NHS
cohort, higher caffeinated coffee intake was also associated with
better objective cognitive performance. Compared with participants in
the lowest quartile, those in the highest quartile had a higher mean
TICS score (mean difference, 0.11 [95% CI, 0.01 to 0.21]) and a higher
mean global cognition score (mean difference, 0.02 [95% CI, −0.01 to
0.04]); however, the association with global cognition was not
statistically significant (P = .06). Higher intake of tea showed
similar associations with these cognitive outcomes, whereas
decaffeinated coffee intake was not associated with lower dementia risk
or better cognitive performance. A dose-response analysis showed
nonlinear inverse associations of caffeinated coffee and tea intake
levels with dementia risk and subjective cognitive decline. The most
pronounced associated differences were observed with intake of
approximately 2 to 3 cups per day of caffeinated coffee or 1 to 2 cups
per day of tea.
Conclusions and Relevance
Greater consumption of caffeinated coffee and tea was
associated with lower risk of dementia and modestly better cognitive
function, with the most pronounced association at moderate intake
levels.
No comments:
Post a Comment